Johnson & Johnson (JNJ) Shares Sold by Fayerweather Charles

Fayerweather Charles trimmed its position in Johnson & Johnson (NYSE:JNJ) by 1.5% during the 4th quarter, Holdings Channel reports. The firm owned 21,365 shares of the company’s stock after selling 316 shares during the period. Johnson & Johnson comprises about 4.9% of Fayerweather Charles’ investment portfolio, making the stock its biggest position. Fayerweather Charles’ holdings in Johnson & Johnson were worth $2,757,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in JNJ. Horan Securities Inc. raised its stake in shares of Johnson & Johnson by 122.3% in the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after buying an additional 241 shares during the period. Stuart Chaussee & Associates Inc. raised its stake in Johnson & Johnson by 20.7% during the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 80 shares during the period. FNY Investment Advisers LLC raised its stake in Johnson & Johnson by 594.4% during the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock valued at $64,000 after purchasing an additional 428 shares during the period. CKW Financial Group raised its stake in Johnson & Johnson by 18.8% during the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock valued at $105,000 after purchasing an additional 128 shares during the period. Finally, Mackey Komara & Dankovich LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $148,000. 67.33% of the stock is currently owned by institutional investors and hedge funds.

NYSE:JNJ opened at $142.01 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.20 and a current ratio of 1.47. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.99. The company has a market capitalization of $381.00 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 2.44 and a beta of 0.67.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.07. Johnson & Johnson had a return on equity of 35.79% and a net margin of 17.99%. The business had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. During the same quarter in the previous year, the company posted $2.06 EPS. The company’s revenue was up .1% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 11th. Shareholders of record on Tuesday, May 28th will be paid a $0.95 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. The ex-dividend date of this dividend is Friday, May 24th. This represents a $3.80 dividend on an annualized basis and a yield of 2.68%. Johnson & Johnson’s payout ratio is presently 44.01%.

Several analysts recently issued reports on JNJ shares. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, January 8th. Wells Fargo & Co reissued an “outperform” rating and set a $152.00 target price (down previously from $162.00) on shares of Johnson & Johnson in a research note on Monday, January 14th. Barclays reissued an “equal weight” rating and set a $135.00 target price (down previously from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Citigroup lifted their target price on Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a research note on Monday, February 25th. Finally, Raymond James lifted their target price on Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $146.40.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/04/johnson-johnson-jnj-shares-sold-by-fayerweather-charles.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What is an overbought condition?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.